Answers are grounded in this paper and cite their sources.
The protein‐protein interaction between programmed cell death protein 1 (PD‐1) and programmed cell death ligand 1 (PD−L1) proteins is one of the major checkpoint inhibition pathways responsible for the escape of tumors from immune destruction. Therefore, inhibition of the PD‐1/PD−L1 interaction presents an important therapeutic target against such tumors that express PD−L1 on their cell surface. Herein, we report structure‐based virtual screening of the National Cancer Institute Diversity Set compounds leading to the identification of several small‐molecule inhibitors of PD‐1/PD−L1 interaction. Top 4 molecules significantly inhibited PD‐1/PD−L1 interaction in a dose‐dependent manner, with the most active molecule (NSC149050) exhibiting ∼50% inhibition at 25 μM test concentration. This is remarkable considering it has a relatively low molecular weight and still is capable of inhibiting PD‐1/PD−L1 protein‐protein interaction whose binding interface spans over ∼1.970 Å 2 . Thus, these molecules may prove well suited for lead optimization studies leading to design of more potent analogs with improved drug‐like properties against this traditionally challenging anticancer target.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: